BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-41@catalystbrief.girapphe.com
DTSTAMP:20261117T061549Z
LAST-MODIFIED:20261117T061549Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Shanghai JMT-Bio Inc. — KN026 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Phase III Study of KN026 in Combi
 nation With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Lo
 cally Advanced HER2-Positive Breast Cancer.\nSource: https://clinicaltrial
 s.gov/study/NCT06747338\nhttps://catalystbrief.girapphe.com/e/41?lang=en\n
 Not investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/41?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
